Firm patent wall of ‘Nexavar,’ a liver cancer treatment, to overcome for domestic companies

The challenges of domestic pharmaceutical companies to nullify the period extension of the substance patent of ‘Nexavar(sorafenib tosilate, Bayer),’ a liver cancer targeted treatment, have encountered difficulties.

According to the industry concerned on the 6^th, Huons, a domestic medium-sized company, filed a decision for the nullification of the existence period extension of the Nexavar’s sub...